Updated HIV treatment guidelines address payer barriers and add Bixlenvo

Bictegravir/lenacapavir (Bixlenvo) is now part of federal guidance on switching antiretroviral therapy (ART) for people whose HIV is already suppressed, the Panel for the Use of Antiretroviral Agents in Adults and Adolescents With HIV announced today in an update to its treatment guidelines. The same update endorses statin therapy for all people with HIV ages 40 to 75 and classifies HIV as a cardiovascular risk enhancer.

Where Bixlenvo fits in HIV switch guidance

The FDA approved Bixlenvo for the treatment of HIV in August. When the panel last updated the guidelines in September, it noted the approval and said it was still reviewing the available information. The new update adds the regimen to the section on optimizing ART in the setting of viral suppression, which covers regimen changes for people whose virus is already controlled.

The panel’s reasoning for these switches is to maintain viral suppression without jeopardizing future treatment options. Reasons people switch medications can include side effects, drug interactions, pill burden and cost.

Before choosing a new regimen, clinicians should review a person’s full antiretroviral history, including virologic responses, past toxicities and intolerances, and cumulative resistance test results. The panel rates this a strong recommendation supported by randomized trial data. People with no history of drug resistance or virologic failure can switch to any regimen shown to be highly effective in people new to treatment or to regimens studied extensively in optimization trials. The panel recommends against monotherapy as a switch strategy and advises close monitoring of adherence, tolerability, safety and viral suppression during the first three months after a switch.

The panel also made related updates to the guidelines’ cost considerations section, drug characteristics tables and dosing recommendations for adults with renal or hepatic insufficiency.

Statin therapy for people with HIV ages 40 to 75

The panel said it concurs with the strong recommendation in the 2026 American College of Cardiology, American Heart Association and HIV Medicine Association Multisociety Dyslipidemia Management Guideline to start statin therapy in all people with HIV ages 40 to 75, regardless of low-density lipoprotein cholesterol level or estimated atherosclerotic cardiovascular disease (ASCVD) risk.

The panel first issued statin guidance for people with HIV in 2024, following the REPRIEVE trial, which evaluated statin therapy specifically in this population. The results showed an approximately 35% reduction in major cardiac events in adults ages 40 to 75 with HIV taking a statin.

The revised cardiovascular complications section adds guidance on risk estimation and primary prevention of ASCVD, classifies HIV as an ASCVD risk enhancer and includes considerations for people with HIV who are hesitant to start statins. The panel also updated lipid monitoring guidance in its laboratory testing table. It has previously cautioned that some statins and antiretrovirals interact in ways that may require a dose adjustment, a different statin or closer monitoring.

What the HIV guidelines say about payer barriers and ART costs

The guidelines also include expanded cost and coverage recommendations the panel added last month. They state that out-of-pocket costs may need to factor into regimen selection because they directly affect affordability, adherence and treatment outcomes, and that coverage changes can cause lapses in viral suppression.

The panel recommends that providers routinely assess what people with HIV pay directly for ART and be prepared to modify regimens when cost becomes a barrier to starting or staying on treatment. When payers stand in the way of a clinically indicated regimen, clinicians should challenge the coverage determination through peer-to-peer review, formal appeals and referral to pharmacy staff, benefits managers or others experienced with HIV-specific coverage. The guidelines also note that disengagement from care is more common during coverage transitions, such as switching insurance or moving to Medicare.

The Ryan White HIV/AIDS Program, the payer of last resort for people with HIV, serves more than 600,000 people with low incomes or limited coverage, according to testimony from the HIV and Hepatitis Policy Institute. The Save HIV Funding campaign has reported that 19 state AIDS Drug Assistance Programs are projecting budget deficits.

Any cost-driven switch, the panel said, must be weighed against a person’s treatment history, prior virologic responses, drug resistance, risk of side effects and the potency and durability of the alternative regimen. “Modifying an ART regimen for cost considerations must never compromise virologic efficacy or long-term treatment outcomes,” the panel wrote.